New Zealand markets closed
  • NZX 50

    11,103.79
    -21.45 (-0.19%)
     
  • NZD/USD

    0.5645
    -0.0019 (-0.33%)
     
  • NZD/EUR

    0.5757
    -0.0022 (-0.38%)
     
  • ALL ORDS

    6,976.10
    -57.40 (-0.82%)
     
  • ASX 200

    6,762.80
    -54.70 (-0.80%)
     
  • OIL

    88.64
    +0.19 (+0.21%)
     
  • GOLD

    1,719.00
    -1.80 (-0.10%)
     
  • NASDAQ

    11,485.50
    -87.68 (-0.76%)
     
  • FTSE

    6,994.89
    -2.38 (-0.03%)
     
  • Dow Jones

    29,926.94
    -346.93 (-1.15%)
     
  • DAX

    12,409.59
    -61.19 (-0.49%)
     
  • Hang Seng

    17,775.89
    -236.26 (-1.31%)
     
  • NIKKEI 225

    27,116.11
    -195.19 (-0.71%)
     
  • NZD/JPY

    81.8250
    -0.3040 (-0.37%)
     

Therapeutic Solutions International Reports Superior Efficacy of ApoptoCyte™ on Chronic Obstructive Pulmonary Disease Model Compared to Conventional Stem Cell Approaches

·2-min read

Phase III Clinical Stage Company Demonstrates Superior Efficacy of Proprietary Stem Cell Apoptotic Body Based Drug

ELK CITY, Idaho, August 12, 2022--(BUSINESS WIRE)--Therapeutic Solutions International announced today new data demonstrating superior effects of the Company’s ApoptoCyte procedure treated JadiCell product compared to other stem cells in treating an animal model of Chronic Obstructive Pulmonary Disease (COPD).

In a series of experiments, mice were administered the enzyme elastase to mimic COPD. It was shown that untreated JadiCell stem cells, as well as stem cells from sources conventionally utilized, specifically fat and bone marrow, had some therapeutic activity including reduction of inflammation, stimulation of regenerative growth factors, and preservation of alveoli structure1. All cell types had improved therapeutic activity when processed using the ApoptoCyte procedure, with JadiCell possessing the highest activity.

"In May of this year we announced and filed a patent on the ApoptoCyte procedure which involves the induction of cellular suicide in the stem cell, extraction of small vesicles called "apoptotic bodies" and co-administration with specific drugs such as certain histone deacetylase (HDAC) inhibitors. Leveraging this technology, we have filed a new patent on COPD which contains the data disclosed today," said Dr. James Veltmeyer, Chief Medical Officer of the Company, and co-inventor of both patents. "The demonstration that the ApoptoCyte Procedure is applicable to COPD, which is one of the major causes of death in the world, is extremely exciting."

The Company possesses IND #28508 for using non-modified JadiCells for COPD, however the clinical trial is expected to initiate following further discussions between the Company and the FDA. Additionally, the Company currently is running a Phase III clinical trial using JadiCells for treatment of advanced COVID-19 infection.

"COPD represents a significant unmet medical need for which no curative approaches exist," said Timothy Dixon, President, and CEO of the Company and co-inventor of the patents. "We are grateful to have a team of cellular and COPD experts who have assisted us in creating what we believe is a first in class approach to treating COPD. We hope to continue exploring the applicability of the ApoptoCyte Procedure in other therapeutics in the regenerative medicine space."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

1 Therapeutic Solutions International Announces ApoptoCyte Procedure for Enhancing Stem Cell Activity | BioSpace

View source version on businesswire.com: https://www.businesswire.com/news/home/20220812005201/en/

Contacts

Timothy G. Dixon
ir@tsoimail.com